Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine

NCT01992016 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT01992016
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01992016 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine
Lead sponsor
University of Colorado, Denver
Phase
Not applicable
Overall status
Completed
Start date
April 7, 2014
Completion date
April 11, 2018
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the prostate, bone metastases, soft tissue metastases, stage iia prostate cancer, stage iib prostate cancer, stage iii prostate cancer, stage iv prostate cancer